PI3K-δ过度激活易致B细胞淋巴瘤
该综述聚焦活化型磷脂酰肌醇3-激酶-δ综合征(APDS)患者的肿瘤并发症,尤其是B细胞淋巴瘤。APDS由PIK3CD或PIK3R1基因突变导致PI3K-δ活性失控,表现为感染易感、淋巴增殖和恶性肿瘤风险增加。文章汇总了APDS中观察到的不同肿瘤类型,并讨论B细胞和T细胞中PI3K-δ失控活性如何驱动恶性转化。
要点
- APDS由PIK3CD或PIK3R1突变致PI3K-δ过度激活。
- APDS以感染易感、淋巴增殖和自身免疫为特征。
- 恶性肿瘤尤其是B细胞淋巴瘤是APDS主要并发症。
核心结论
- APDS中PI3K-δ过度激活易导致B细胞淋巴瘤等恶性肿瘤,显著恶化预后。
研究设计与样本
- 综述,总结APDS患者中观察到的肿瘤性疾病及PI3K-δ活性失控致恶性转化的机制。
主要发现
- 1型和2型APDS由不同基因突变引起,但均导致PI3K-δ活性过高,临床表现相似。
- APDS患者对细菌和病毒感染易感性增加,并可有自身免疫表现。
- 淋巴增殖是APDS的标志,可能危及生命并需反复手术治疗。
- 恶性肿瘤尤其是B细胞淋巴瘤是APDS的主要并发症,极大恶化预后。
临床怎么用
- 对APDS患者应警惕B细胞淋巴瘤等恶性肿瘤的发生。
- APDS患者出现淋巴增殖时需评估恶性转化风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Activated phosphatidylinositol 3-kinase-δ (PI3K-δ) syndrome (APDS) is a rare primary combined immunodeficiency caused by either dominant gain-of-function mutations in the PIK3CD gene encoding the catalytic subunit p110δ of PI3K-δ (referred to as type 1 APDS) or dominant loss-of-function mutations in the PIK3R1 gene encoding the p85α, p55α, and p50α regulatory subunits (type 2 APDS). In types 1 and 2 APDS, the PI3K-δ hyperactivity resulting from the gene mutations leads to similar clinical presentations, characterized by increased susceptibility to bacterial and viral infections and (to a lesser extent) autoimmune manifestations. A hallmark of this disease is lymphoproliferation, which may even be life threatening and require repeated surgical treatment. A major complication of APDS is malignancy (especially B-cell lymphomas), which greatly worsens the prognosis. Here, we review the different neoplastic conditions observed in patients with APDS and discuss the uncontrolled PI3K-δ activity in B and T cells that leads to malignant transformation.
引用
- Durandy A, Kracker S. Increased activation of PI3 kinase-δ predisposes to B-cell lymphoma. Blood. 2020. PMID: 31942637. doi:10.1182/blood.2019002072
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。